1,076 results
Page 5 of 54
6-K
EX-99.1
evr u6jpnvls
17 Aug 22
Sanofi provides update on amcenestrant clinical
1:18pm
6-K
pigsy
11 Aug 22
Current report (foreign)
3:24pm
6-K
EX-99.1
cerlj3 lvuvsl9pivx76
11 Aug 22
Current report (foreign)
3:24pm
6-K
EX-99.1
ugh68tpphi 0dlxz78
8 Aug 22
Sanofi and Innovent Biologics enter strategic
4:27pm
6-K
EX-99.2
l6ur kab9
8 Aug 22
Sanofi and Innovent Biologics enter strategic
4:27pm
6-K
EX-99.1
27l5ak7tyk7qala l3k
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.1
fexldcp
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.2
xx9znpn2
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
855kwgr
20 Jul 22
Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
12:38pm
6-K
EX-99.1
p3t7jt0eu9bkq uzky6c
13 Jul 22
Current report (foreign)
1:40pm
6-K
EX-99.2
ovqese16tgvqrvb
13 Jul 22
Current report (foreign)
1:40pm
6-K
EX-99.1
bcjte5mjxg dvypr1mex
8 Jul 22
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
11:01am
6-K
EX-99.1
s1afkp i4
30 Jun 22
Current report (foreign)
12:10pm
6-K
EX-99.3
4int5tqw 8x0az24j4d8
28 Jun 22
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
3:59pm
6-K
EX-99.1
4iud0toqq
28 Jun 22
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
3:59pm
6-K
EX-99.2
e4dslu
28 Jun 22
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
3:59pm
6-K
EX-99.1
i185jk
16 Jun 22
Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
1:20pm
6-K
EX-99.3
l5ug48x9
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.1
7be9q z47v0x
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.2
70k9qkih3dr
7 Jun 22
Current report (foreign)
2:51pm